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Summary 
 
Despite numerous guidelines on the management of anaemia in surgical patients, 
there is no pragmatic guidance for the diagnosis and management of anaemia and 
iron deficiency in the postoperative period. A number of experienced researchers 
and clinicians took part in a two-day expert workshop and developed the following 
consensus statement. After presentation of our own research data and local policies 
and procedures, appropriate relevant literature was reviewed and discussed. We 
developed a series of best-practice and evidence-based statements to advice on 
patient care with respect to anaemia and iron deficiency in the postoperative period. 
These statements include: a diagnostic approach for iron deficiency and anaemia in 
surgical patients; identification of patients appropriate for treatment; and advice on 
practical management and follow-up that is easy to implement. Available data allow 
the fulfilment of the requirements of Pillar 1 of Patient Blood Management. We urge 
national and international research funding bodies to take note of these 
recommendations, particularly in terms of funding large-scale prospective, 
randomised clinical trials that can most effectively address the important clinical 
questions and this clear unmet medical need.   
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Recommendations for best clinical practice 
 
• All patients who have undergone major surgery (defined as blood loss > 500 
ml or lasting > 2 hrs) and who had pre-operative anaemia or moderate-to-
severe blood loss during surgery must be screened for anaemia after surgery. 
• During recovery from uncomplicated major surgery, haemoglobin 
concentrations should be monitored, either by standard laboratory or point-
of-care testing, on a regular daily basis, at least until the third postoperative 
day, to detect anaemia (haemoglobin < 130 g.l-1 for men, <120 g.l-1 for 
women). 
• Postoperatively, iron deficiency should be defined by ferritin concentration 
<100 µg.l-1, ferritin <100-300 µg.l-1 and transferrin saturation <20%, or 
reticulocyte haemoglobin content <28 pg. High blood loss during surgery may 
also indicate the need for iron replacement in anaemic patients. 
• In the postoperative period, when the administration of iron is necessary, 
early intravenous iron therapy is recommended, after considering 
contraindications. Where possible, it should be administered using a single 
high-dose preparation for the repletion of iron stores 
• For non-cancer patients with severe postoperative anaemia and 
inflammation-induced blunted erythropoiesis, or those declining blood 
transfusion, we suggest considering additional treatment with an 
erythropoiesis stimulating agent. 
• If patient blood management measures did not prevent the development of 
severe postoperative anaemia, the adoption of a restrictive transfusion 
threshold is recommended (haemoglobin level: 70-80 g.l-1, depending on 
patient’s comorbidities) is recommended in most adult, clinically-stable 
hospitalised patients. 
• We recommend establishing a Patient Blood Management expert group in 
every hospital.  
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Why was this consensus statement developed?  
 
The concept ‘patient blood management (PBM) is defined as “the timely application 
of evidence based medical and surgical concepts designed to manage anaemia, 
optimise haemostasis, and minimize blood loss in order to improve patient outcomes 
after surgery” [1]. Patient blood management has been shown to reduce transfusion, 
healthcare costs and morbidity and mortality [2]. Treatment of pre-operative anaemia 
and isolated iron deficiency are crucial measures for PBM [3.4]. However, detection 
and early treatment of pre-operative anaemia and iron deficiency is an accepted 
logistical challenge and, as a consequence, some patients may undergo surgery 
without the chance to address their anaemia [3]. In addition, there has been increased 
emphasis on the use of restrictive transfusion thresholds in order to accelerate 
recovery and discharge after surgery as well as improve outcomes and reduce 
transfusion requirements, which may have led to overlooking potential opportunities 
to optimise anaemic patients and improve their functional recovery [5,6]. Therefore, 
an additional focus on the early detection and treatment of postoperative iron 
deficiency and anaemia is a novel and complementary measure within the concept of 
PBM which allows the attending physician to target patients who lost significant red 
cell mass during surgery and may require specific attention postoperatively or post-
discharge [7]. 
How does this consensus statement differ from other available statements and/or 
guidelines?  
 
There are a number of statements and guidelines from professional associations 
recommending a systematic approach to this problem for the management of 
preoperative anaemia [1,7-15]. Most of these guidelines also recommend the use of 
a restrictive transfusion threshold for treating acute postoperative anaemia, but 
recommendations for pharmacological management of anaemia are scarce or even 
absent [1,7-15]. The aim of this document is to update and utilise the few current 
recommendations therein and with a panel of experts provide a working practice 
document, based on scientific evidence and clinical experience, on ‘how to’ feasibly 
introduce these postoperative anaemia guidelines into clinical practice. Therefore, our 
goal is to provide pragmatic, clear easy-to-follow clinical guidance for the diagnosis 
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and treatment of postoperative anaemia and iron deficiency in order to improve 
patient recovery, reduce the need for blood transfusion and improve functional 
outcomes in a cost-effective manner. Our recommendations are intended for non-
actively bleeding adult patients in whom all the principles of PBM have been 
implemented pre- and intra-operatively for the prevention of postoperative iron 
deficiency and anaemia. 
 
Definition, prevalence and pathophysiology of postoperative anaemia  
 
Postoperative anaemia may be present in up to 80-90% of patients undergoing major 
surgery, although this prevalence varies widely according to different definitions 
[16,17]. Anaemia is defined by the World Health Organization (WHO) as a 
haemoglobin concentration <130 g.l-1 for men, <120 g.l-1 for non-pregnant women and 
<110 g.l-1 for pregnant women [18]. Although debated [19], and since these definitions 
are widely accepted, they may apply to postoperative patients. However, we 
previously pointed out that the WHO criteria for the definition of anaemia may not be 
reliable for the classification of non-pregnant women undergoing surgical procedures 
with expected moderate-to-high blood loss. Women have lower circulating blood 
volumes and reduced red cell mass compared to males, but the same procedures 
performed in either gender often result in comparable amounts of blood loss, 
resulting in higher transfusion rates in females [4].  Therefore, pre-operative anaemia 
in non-pregnant women should be defined as for men as a haemoglobin concentration 
< 130 g.l-1.   
According to the WHO, postoperative anaemia could be classified as mild 
(haemoglobin 100-119/129 g.l-1), moderate (haemoglobin 80-100 g.l-1) or severe 
(haemoglobin <80 g.l-1) [18].  
Although multi-factorial in origin (Table 1), pre-operative anaemia, peri-operative 
blood loss (surgical bleeding, coagulopathy, phlebotomies, etc.), and postoperative 
blunted erythropoiesis are the main contributing factors to postoperative anaemia 
after major surgery. Haemodilution due to excessive fluid administration, which may 
cause ‘dilutional’ anaemia or aggravate pre-existing anaemia, and other nutritional 
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deficiencies (e.g., vitamin B12, folic acid) and pharmacological interactions are also 
contributing factors [20].  
Low pre-operative haemoglobin, female sex and smaller body surface area have been 
identified as risk factors for the development of postoperative anaemia and increased 
transfusion needs [21]. Additionally, in the general population, the prevalence of 
anaemia increases with age and older persons are more likely to undergo major 
surgery and to present with comorbidities, thus increasing the risk of postoperative 
anaemia, and reducing its tolerability [22,23]. 
The end of the surgical procedure does not always signify the end of blood loss. 
Ongoing postoperative blood loss can continue through drains or into traumatised 
tissue, or due to repeated phlebotomies during a prolonged postoperative period. As 
such, peri-operative blood loss may result in acute or late postoperative anaemia, 
especially in patients with the above mentioned risks factors. To avoid the detrimental 
effects of acute anaemia, packed red blood cells are usually transfused, as a default 
measure [20]. However, the use of restrictive transfusion threshold, as emphasised in 
the third pillar of PBM, also contributes to a higher prevalence of moderate-to-severe 
anaemia on discharge from hospital (haemoglobin concentration <100 g.l-1), unless 
pro-active measures are implemented [20]. 
Anaemia in the postoperative period, as well as in critical illness, may be aggravated 
by reduced erythropoietin production and secretion due to inflammatory mediators; 
blunted bone marrow response to erythropoietin; and decreased iron availability due 
to down-regulation of intestinal absorption and impaired mobilisation of iron from 
body stores (Table 1) [24,25]. Inflammatory cytokines stimulate the secretion of 
hepcidin, a hormone that targets ferroportin, the only known cellular exporter of iron. 
This induces the internalisation and degradation of ferroportin, thereby largely 
inhibiting intestinal iron absorption and greatly reducing iron release from body stores 
(iron sequestration) [26].  
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What are the unmet medical needs of postoperative anaemia? 
 
The concerns surrounding postoperative anaemia relate to its potential impact on 
recovery, rehabilitation, hospital re-admission or re-operation, and patients’ 
wellbeing. Reducing allogeneic blood transfusion improves long-term outcome and 
survival [27]. However, restrictive transfusion protocols have led to patients being 
discharged with lower haemoglobin levels than before. With the current paucity of 
data, it remains unclear whether a lowered discharge haemoglobin level may allow 
optimal functional recovery and quality of life [28-34]. There has been limited research 
on the consequences of postoperative anaemia in the recovery phase from surgery, 
with only a small number of studies after cardiac and hip and knee surgery, which 
demonstrated the association between postoperative anaemia and adverse outcomes 
such as prolonged recovery, increased mortality and likelihood of re-admission [31-
33]. Postoperative anaemia may also potentially be associated with early 
postoperative myocardial infarction [34].  Correction of postoperative anaemia, as 
suggested in this consensus statement, is intended to prevent side effects, but studies 
are urgently needed to prove this. 
 
Diagnosis of postoperative anaemia 
 
When and how to measure haemoglobin concentration?  
Measurement of haemoglobin concentration is a routine procedure in postoperative 
care. Duration of testing for postoperative anaemia depends on the peri-operative 
bleeding risk associated with the surgical intervention and patient-dependent factors. 
In most cases of uncomplicated recovery from surgery, a nadir in haemoglobin 
concentration can be observed within the first 3-4 days after surgery. In patients with 
major complications following major surgery, however, prolonged hospitalisation and 
exposure to low haemoglobin levels increase the duration of monitoring required.   
Usually, blood gas analysis, capillary sampling (e.g., HemoCue, HemoCue AB, 
Ängelholm, Sweden) or near-infrared spectroscopy (e.g., Radical-7, Masimo 
Corporation, Irvine, CA, USA) are performed as a point-of-care assessment, while the 
full blood count is tested in the central laboratory. The use of non-invasive continuous 
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haemoglobin monitoring devices instead of phlebotomy may reduce blood loss, pain 
and discomfort for the patient, but concerns about precision limit routine clinical use. 
Although the debate focuses on accuracy of a single check [35], the reliability of non-
invasive haemoglobin monitoring devices for dynamic changes over time may permit 
detection of occult bleeding and response to therapy [36].  
What are the confounding factors? 
In the setting of postoperative care, a number of confounding factors may impact on 
accurate haemoglobin measurement. Volume overload and haemodilution after 
major surgery are potential causes for low haemoglobin levels, despite normal and 
stable red cell mass. Therefore, the diagnosis of anaemia based on simple 
haemoglobin concentration may be misleading and is confounded by plasma volume 
derangements resulting in significant over-diagnosis [37]. Potential volume overload 
should be taken into account and may improve after diuresis.  
Similar conditions may be present in the peri-operative setting where prevention of 
intravascular volume deficit is a cornerstone of peri-operative management. Here, 
intravascular volume and fluid therapy is fundamental whenever fasting is indicated 
for medical reasons, in the event of high-fluid turnover rates during major surgery, or 
in cases of reduced enteral resorption because of sustained vomiting, severe 
diarrhoea or gastro-intestinal dysfunction following circulatory shock. The primary 
aim of fluid therapy (crystalloids and colloidal solutions) is the restoration of plasma 
and blood volume to ensure appropriate cardiac output and tissue perfusion. 
Unfortunately, appropriate assessment of the volume status is complex. The diagnosis 
or quantification of moderate-to-severe volume deficit and volume responsiveness 
remains difficult, and may be attempted using laboratory variables (e.g. lactate, base 
excess), positional manoeuvres (passive lifting of legs), new monitoring devices 
(measuring pulse variability and stroke volume indexes or other preload variables) or 
echocardiography. Recent guidelines highlight the importance of avoiding 
hypervolaemia [7]. During postoperative recovery, redistribution and excretion of 
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fluids may lead to rapid recovery of haemodilution-induced low haemoglobin 
concentrations. 
When and how to measure postoperative iron deficiency? 
Although underlying causes of postoperative anaemia are multifactorial, iron 
deficiency is often present. While pre-operative iron deficiency can be diagnosed on 
the basis of low ferritin concentrations [4], diagnosis of postoperative iron deficiency 
is more difficult as ferritin levels may be elevated as part of the acute phase 
inflammatory response after surgery [38]. Thus, patients undergoing major surgery 
with a high risk of developing moderate-to-severe postoperative anaemia should have 
their haemoglobin and iron status checked on the day of surgery, if it has not been 
already performed in the pre-operative assessment. This may also apply to patients 
with ongoing bleeding and anaemia (e.g. colorectal cancer) that have been treated in 
the pre-operative period. As ferritin levels will be not elevated by inflammation 
immediately after surgery, a postoperative ferritin concentration <100 µg.l-1 on day of 
surgery indicates insufficient iron stores to support erythropoiesis after procedures 
with significant postoperative haemoglobin drop [8].  
Further markers for postoperative iron deficiency are transferrin saturation <20% with 
ferritin concentrations 100-300 g.l-1, or reticulocyte haemoglobin content <28 pg. 
These values and parameters may signal the need for intervention in anaemic patients 
[38-40]. 
When should postoperative anaemia be treated?  
There is limited supporting data regarding appropriate timing for management of 
anaemia after surgery including red cell transfusion. Treatment choice depends on 
severity and type of anaemia, type of surgery, patient comorbidities and presence of 
any surgical complications.   
Iron supplementation should be considered in patients with iron deficiency or 
significant a significant reduction in postoperative haemoglobin, starting early in the 
postoperative recovery phase with no major complications [39,42-46]. It is important 
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to note that there are no studies identifying the best moment to start postoperative 
iron supplementation.  
For non-cancer patients with severe postoperative anaemia and inflammation-
induced blunted erythropoiesis or those declining blood transfusion, additional 
treatment with an erythropoiesis stimulating agent (e-g., recombinant human 
erythropoietin [rHuEPO]) may be considered. However, we are aware that for patients 
without a previous indication this is an off-label use of rHuEPO, and recommendations 
vary across countries [10,12,15]. 
Red cell transfusion should be restricted to patients with severe anaemia 
(haemoglobin <70-80 g.l-1) and clinical signs and symptoms [7,10-12,47-49]. Red cell 
transfusion should be considered in patients with active bleeding and in those severely 
anaemic once bleeding has been stopped [7,10-12,47-49]. However, more research is 
required on specific transfusion thresholds in specific high-risk patients. 
How should patients be treated postoperatively?   
 
Pharmacological optimisation of postoperative haemoglobin and erythropoiesis 
should allow correction of iron deficiency and rapid recovery from postoperative 
anaemia which can lead to improved postoperative outcomes and improved quality 
of life. It may also result in a reduction of patient’s exposure to red cell transfusion 
and its related risk and complications, thus contributing further to improving surgical 
outcome and patient safety.   
Iron therapy: oral vs. intravenous iron?  
The National Institute for Health and Care Excellence in the UK (NICE) recommends 
offering oral iron after surgery to patients with iron deficiency anaemia [12]. However, 
in the postoperative period, oral medications may not be tolerated or absorbed and 
have several limitations including frequent gastro-intestinal side effects and, as a 
consequence, poor treatment adherence. Additionally, the inflammatory response 
induced by surgery stimulates hepcidin synthesis and release, which in turn inhibits 
intestinal iron absorption, making oral iron therapy largely ineffective [10,13,50]. 
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Various randomised placebo controlled trials (RCTs) in orthopaedic and cardiac 
surgery patients have demonstrated that oral iron therapy was not better than 
placebo in correcting postoperative anaemia and reducing transfusion requirements 
[51-57].  
On the other hand, NICE recommends considering intravenous (i.v.) iron after surgery 
for patients who have iron deficiency anaemia and cannot tolerate or absorb oral iron, 
or are unable to adhere to oral iron treatment, as well as for those who are diagnosed 
with functional iron deficiency [12]. Thus, patients with uncorrected pre-operative 
iron deficiency (ferritin <100 g.l-1) and/or moderate-to-severe postoperative 
anaemia (haemoglobin <100 g.l-1) may benefit from i.v. iron supplementation, which 
has proven to be more effective than oral iron in a number of surgical settings (On-
line appendix 1) [39,42-45,58-62]. Most recent RCTs have shown a benefit of high-
dose postoperative i.v. iron (e.g., 1000 mg) as demonstrated by increased Hb and/or 
reduction of transfusion requirements, and no i.v. iron-related serious adverse events 
were reported (On-line appendix 1) [39,42,44,45]. Importantly, in orthopaedic surgical 
patients with postoperative haemoglobin <100 g.l-1 and/or uncorrected preoperative 
iron deficiency, a great rise in Hb and better scores for 'usual activities' were observed 
with high dose i.v. iron compared with oral iron [42].  
Similarly, compared with oral iron, the use of i.v. iron for treating post-partum 
anaemia has been shown to result in greater and faster Hb increase, better 
replenishment of iron stores, lower incidence of adverse side-effects and greater 
improvement in quality of life [15,46].   
Therefore, should postoperative iron therapy be indicated, i.v. formulations are 
recommended. This is in line with recent management guidelines in surgical patients 
experiencing severe bleeding (GRADE 2C for i.v. iron preparations postoperatively) [7]. 
For calculating the total iron dose, it is important to take into account the preoperative 
haemoglobin level and iron status, the magnitude of postoperative haemoglobin drop, 
and whether patients have received postoperative red cell transfusion (Figure 1). The 
use of i.v. iron formulations which allow quick (15-60 mins) infusion of high iron doses 
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(1000 mg or more) offers added convenience to both physicians and patients and 
should be preferred, despite their higher cost (Table 1) [40,64]. 
 
Which are the true risks and contra-indications for intravenous iron? 
Many clinicians and health authorities still consider that i.v. iron has a high association 
with major side effects, such as anaphylaxis, infections or oxidative stress. However, 
these side effects appear to be not significant with the newer i.v. iron preparations, 
such as ferric carboxymaltose, iron isomaltoside and low molecular weight iron 
dextran [64-66].  
 
After an extensive data review, the European Medicines Agency’s Committee for 
Medicinal Products for Human Use (CHMP) concluded that “all i.v. iron medicines have 
a small risk of causing allergic reactions which can be life-threatening if not treated 
promptly” [67]. However, the reported incidence of potentially life-threatening 
hypersensitivity reactions (<1:250.000 administrations) is vastly overestimated and 
the pathophysiological mechanism poorly understood, though a substantial 
proportion is thought to be mediated by complement activation, resulting 
complement activation-related pseudo allergy (CARPA)[68,69]. Minor infusion 
reactions due to ‘labile’ iron may occur, but are usually self-limiting without 
intervention and should not be misinterpreted as acute hypersensitivity events 
[65,70].   
The CHMP’s review also concludes that “the benefits of these medicines are greater 
than their risks, provided that adequate measures are taken to minimise the risk of 
allergic reactions” [67]. To this end, i.v. iron preparations should only be given in an 
environment where resuscitation facilities are available, so that patients who develop 
an allergic reaction can be treated immediately, and patients should be closely 
observed for signs and symptoms of hypersensitivity reactions during and for at least 
30 minutes following each injection of intravenous iron medicine1. Guidelines for 
adequate diagnosis and management of these reactions have been recently published 
[71]. In addition, the CHMP’s report contraindicates the use of i.v. in patients with 
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hypersensitivity to the active substance or excipients, with serious hypersensitivity to 
other parenteral iron products, or in the first trimester of pregnancy [67].   
Elemental iron is an essential growth factor for bacteria, with many species expressing 
iron transport proteins that compete with transferrin, and it has long been suggested 
that patients with iron overload are at increased risk of infection [72]. However, data 
from meta-analyses and large observational studies showed that peri-operative i.v. 
iron did not increase postoperative infection or 30-day mortality rates in surgical 
patients [64,66].  In contrast, red cell transfusion delivers haem and labile iron which 
readily supports bacterial growth more [73]. Nevertheless, in the absence of definitive 
clinical data, it would seem logical to refrain from i.v. iron administration in an acute 
infection setting [8]. 
The available evidence relating i.v. iron administration to oxidative stress leading to 
atherogenesis and vascular remodelling is sparse and indirect. It is mostly derived 
from observational retrospective studies addressing long-term i.v. iron therapy [70], 
while in the postoperative period, very short-term i.v. iron courses are administered 
(one or two large doses) [64]. Thus, it does not seem to be a concern in the 
postoperative setting. 
Should we treat iron deficiency without anaemia?  
A normal haemoglobin level does not exclude iron deficiency. In fact, the WHO 
recognises that ‘mild’ anaemia (haemoglobin 110-130 g.l-1) is a misnomer, as iron 
deficiency is already advanced by the time anaemia is detected, and has consequences 
even when anaemia is not clinically apparent [18].  
Non-anaemic patients with reduced or absent iron stores may have symptoms such 
as fatigue or reduced exercise tolerance, as iron is required for optimal mitochondrial 
function essential for respiration and energy production [40,74].  Current guidelines 
do not recommend routine iron screening in the absence of anaemia. However, the 
benefit of oral or i.v. iron replacement for non-anaemic iron deficiency-associated 
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fatigue has been demonstrated in menstruating women, runners and blood donors 
[75-78]. 
In congestive heart failure, a frequent comorbidity among surgical patients, non-
anaemic iron deficiency was independently associated with compromised physical 
performance and quality of life, and an increase of all-cause and cardiovascular 
mortality; treatment of non-anaemic iron deficiency with i.v. iron may improve 
functional status within four weeks, and reduces hospitalisations for cardiovascular 
reasons and mortality [79,80]. In addition, improvements are maintained after 24 and 
52 weeks [79-81]. 
In observational studies of patients undergoing abdominal or cardiac surgery, pre-
operative non-anaemic iron deficiency was associated with poor outcomes, including 
increased rates of postoperative infection, transfusion, fatigue and longer length of 
hospital stay [82-84]. Though it is presently unknown whether preoperative correction 
of non-anaemic iron deficiency may offset the excess of risk of postoperative 
complications, some guidelines recommend peri-operative iron supplementation for 
patients with non-anaemic iron deficiency [14,85].   
Secondary thrombocytosis can be also seen after major surgery, as platelets behave 
as an acute phase reactant. Iron deficiency has also been shown to induce secondary 
thrombocytosis in several clinical settings. Correction of iron deficiency usually lowers 
platelet count and platelet activation in patients with chronic kidney disease, cancer 
or inflammatory bowel disease-associated secondary thrombocytosis, and might 
contribute to reduced risk of thrombo-embolic events [86-89].  
Is there a role for erythropoiesis stimulating agents? 
In patients without a previous indication, postoperative administration of 
recombinant erythropoietin [rHuEPO] is an off-label use of this medicinal product. The 
effects of postoperative rHuEPO have been evaluated in case series, mostly in Jehovah 
Witnesses, and in two RCTs yielding inconclusive results due to selection bias [58] or 
premature interruption [59].  
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In women with moderate-to-severe postpartum anaemia, 5 RCTs evaluated the 
effects of iron sucrose (300-1600 mg) or iron sucrose plus rHuEPO (20,000-40,000 IU) 
on haemoglobin recovery and transfusion needs [15].  A trend to faster Hb increment 
was observed with rHuEPO plus i.v iron compared with i.v. iron alone, but no 
significant differences in transfusion rate were observed, which were very low. The 
benefit seemed to be greatest in rHuEPO-treated subgroup with elevated C-reactive 
protein levels after Caesarean section [15]. 
Though it does not strictly refer to surgical patients, a recent meta-analysis also found 
a reduction of mortality rates (risk ratio [RR] 0.63, 95% CI 0.49–0.79, P < 0.0001) in 
critically ill trauma patients receiving rHuEPO (nine studies, 2607 patients), without 
increasing the risk of thromboembolic complications [90]. In cardiac surgery patients, 
rHuEPO seems to exert a neurologic and renal protective effect [91,92]. The 
mechanisms underlying these non-erythropoietic effects of rHuEPO need to be 
elucidated before recommending its use in patients without an approved indication. 
Short-term pre-operative (1-4 days prior to operation) administration of rHuEPO to 
anaemic patients, with or without i.v. iron, has been shown to reduce postoperative 
transfusion in elective orthopaedic and cardiac surgery [93,94]. In hip fracture repair 
surgery there are conflicting results. One RCT failed to show a reduction in red cell 
transfusion in patients receiving rHuEPO plus i.v. iron [95]. However they included 
patients with haemoglobin <100 g.l-1 and excluded women with haemoglobin ≥120 g.l-
1, and fixed amounts of red cell according pre-defined transfusion thresholds (e.g., 
patients with haemoglobin  ≤70 g.l-1 received 3 units of red cells and those with 
haemoglobin  71 to 89 g.l-1 and severe symptoms received two units). In contrast, an 
observational study in 196 anaemic hip fracture patients managed with perioperative 
i.v. iron and restrictive transfusion protocol, administration of recombinant 
erythropoeitin on admission was associated with reduced transfusion requirements 
and higher haemoglobin levels on discharge and postoperative day 30 [98]. An analysis 
including 544 women with haemoglobin <130 g.l-1  undergoing hip fracture repair 
showed that the blood sparing effect of this strategy was restricted to those 
presenting with haemoglobin concentrations between 120 and 130 g.l-1 (n= 305)[97]. 
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Thus, in non-cancer patients with severe postoperative anaemia and blunted 
erythropoiesis due to infection and/or inflammation, as well as in those who refuse 
blood transfusion, we suggest considering treatment with recombinant human 
erythropoietin. However, some guidelines do not support the off-label use of this 
medicinal product [12]. 
Red blood cell transfusion: transfusion thresholds for whom and when?  
Allogeneic red cell transfusion is associated with a significant increase in peri-
operative morbidity and mortality [2,98-100]. In addition, there is a worldwide 
shortage of blood with substantial associated costs to the manufacturer and health 
systems [101]. Moreover, red cell transfusion harbours the risk of infectious, 
immunological, haemolytic, non-haemolytic adverse reactions, cardiac and pulmonary 
complications [2,98]. Despite successful implementation of PBM programs, red cell 
transfusion is still widely used as a default treatment the majority of patients with 
acute postoperative anaemia [102]. 
Historically, the standard for red cell transfusion was a liberal transfusion threshold, 
namely haemoglobin level <100 g.l-1 (or haematocrit <30%). This arbitrary transfusion 
threshold has been gradually lowered towards haemoglobin 70 – 80 g.l-1, according to 
data derived from a number of randomised controlled trials (RCT) evaluating the effect 
on patients’ outcomes of restrictive versus more liberal red cell transfusion strategies 
in a variety of clinical settings. When subjected to pooled analysis in several systematic 
reviews and meta-analyses (On-line appendix 2) [103-108], data from these RCTs show 
that, in terms of morbidity and mortality, a restrictive red cell transfusion strategy is 
equivalent to or more beneficial than a liberal strategy [101,109] . 
In addition, evidence-based guidelines have translated the results of RCTs and meta-
analyses into clinical practice [7,10-12,47-49]. One of the most recently published 
guidelines on red cell transfusion thresholds recommends a restrictive red cell 
transfusion threshold (haemoglobin <70 g.l-1) for hospitalised adult patients who are 
haemodynamically stable, including critically ill patients [49]. However, a transfusion 
threshold of at least 80 g.l-1 is suggested for patients undergoing orthopaedic surgery, 
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cardiac or oncological surgery, and those with pre-existing cardiovascular disease 
[12,49,110,111]. Nevertheless, transfusion of red cells for higher haemoglobin levels 
should be evaluated case by case considering acute on-going blood loss, comorbidities 
and signs of organ ischaemia or symptoms indicative of hypoxia, and compared with 
postoperative functional recovery and morbidity. In any case, published guidelines, 
agree that red cell transfusion is not beneficial when haemoglobin is >100 g.l-1 [7,10-
12,47-49,112]. Confounding factors on haemoglobin levels have to be considered, as 
discussed above. 
Cost assessment implications 
 
There are very few studies on the cost implications of the management of 
postoperative anaemia. Most such studies have evaluated pre-operative 
interventions, and since the pre-operative haemoglobin value is strongly associated 
with the postoperative haemoglobin, interventions aimed to improve pre-operative 
anaemia also influence postoperative well-being and its related costs [113].  
Costs of anaemia management and PBM may vary from institution to institution and 
depend on the extent to which different aspects of PBM have been implemented. The 
following costs per patient were recently calculated in a single German University 
Hospital: diagnosis of anaemia €49-124; treatment of anaemia (including iron-
deficiency anaemia and megaloblastic anaemia) €13-128 [114]. 
Similarly, data from > 600,000 patients (2008-2014) who were enrolled in a PBM, peri-
operative management programme targeting anaemia and iron deficiency, a risk-
adjusted reduction of postoperative red cell transfusion, infection and mortality rates, 
shorten length of hospital stay, and US$ 78-97 million estimated activity-based savings 
was reported [2]. 
A recent RCT that investigated the use of i.v. iron versus standard care in the 
management of postoperative anaemia did not include a formal cost-analysis; 
however, transfusion rate, infections and hospital stay were decreased, suggesting 
cost effectiveness [39]. A retrospective, matched cohort reported on costs of 
postoperative i.v. iron therapy in total lower limb arthroplasty and found that use of 
iron formulations was cost-neutral (-25.5 to 62.1 €/patient for iron sucrose and -51.1 
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to 64.4 €/patient for ferric carboxymaltose) compared with red cell transfusion [43]. 
In contrast, although NICE guidelines still recommend oral iron in the pre-operative 
and postoperative settings [12], available evidence on the lack of efficacy of oral iron 
in the postoperative period suggests that cost-analysis of this intervention is not 
meaningful [51-57].  
Suggestions for further research  
During the writing of this consensus statement, it became apparent that there are 
areas of postoperative anaemia management for which further research is required: 
 Monitoring. It is really important to emphasise the need for detailed post-
discharge anaemia studies with periodical monitoring of haemoglobin and iron 
parameters in relation to functional recovery.  
 Interventions. More data and clinical trials are required to firmly establish the 
impact of postoperative anaemia management strategies (i.v. iron vs. oral iron, 
recombinant erythropoietin, red cell transfusion, and nutritional support) on 
functional recovery and quality of life, on end–points in addition to laboratory 
end-points, such as haemoglobin increase, and interventional end-points, such 
as reduction or avoidance of red cell transfusion. Further research is required 
to assess the effects of correction of iron deficiency, with or without anaemia, 
on platelet counts, platelet activation, and thromboembolic events, especially 
in the elderly. Timing of interventions in the postoperative course needs to be 
addressed in future trials. Dosing of anti-anaemia treatment and combination 
of means of treatment must be systematically investigated. 
 Patients.  It is also needed to define which patient groups are most likely to 
benefit from such treatments 
 Mechanisms of action. The mechanisms underlying non-erythropoietic effects 
of recombinant erythropoietin, such as neurological and renal protective 
effects, and iron need to be elucidated. 
 Cost. Cost-effectiveness of postoperative anaemia correction must be 
investigated at the different time points for its administration, and a formal 
cost evaluation. Until such data are available, the predominant signal from 
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available publications and peer reviewed recommendation support the 
concept of postoperative anaemia screening, diagnosis and appropriate 
treatment. 
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Legend to figures 
 
Figure 1. Postoperative anaemia management 
 
a. Whenever possible, assess iron status within 24h postop, if it has not 
been already performed in the pre-operative assessment. Monitor 
haemoglobin during 3-4d postop. 
b. According to World Health Organisation’s classification
.
 
c. Appropriate treatment should be considered. 
d. Postoperative ferritin <100 g.l
-1 
, ferritin <300 g.l
-1
 and transferrin 
saturation <20% or reticulocyte haemoglobin content <28 pg. 
e. Due to preoperative anaemia or heavy surgical bleeding. 
f. Total iron deficiency = (target haemoglobin – actual haemoglobin) x 
weight (kg) x 0.24. 
• Add  another 10 mg.kg
-1
 for replenishing iron stores, specially in 
patients with preop iron deficiency. 
• Consider adding recombinant human erythropoietin (40,000 IU) for 
patients with severe anaemia or declining transfusion.  
• For  IV iron dosing schedule, see table 1. 
i.   Transfuse one  red blood cell  unit at the time, with post-transfusion 
reassessment of further needs. Consider IV iron supplementation after 
transfusion, using post-transfusion haemoglobin as actual haemoglobin 
for total iron deficiency calculation. 
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